The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Imatinib + MTC in Relapsed / Refractory Acute Myeloid Leukemia (AML)
Official Title: Open-label Multicenter Trial of Glivec® (Imatinib Mesylate, Formerly Known as STI571) in Combination With Chemotherapy (MTC) in Patients With Refractory or Relapsed Acute Myeloid Leukemia (AML)
Study ID: NCT00744081
Brief Summary: The purpose of this study is to show superiority in complete responses of combination therapy MTC plus Glivec in patients with refractory or relapsed AML compared to a historical control which was treated with MTC alone.
Detailed Description:
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
University of Frankfurt, Medical Dept. II, Frankfurt, , Germany
Name: Lothar Bergmann, MD, PhD
Affiliation: University Hospital of Frankfurt, Medical Dept. II
Role: STUDY_CHAIR